Skip to main content
. 2024 Feb 19;13(3):609–617. doi: 10.1007/s40121-024-00935-0

Table 1.

Clinical cases reported to www.clinicalcasesDDIs.com from May 2019 to March 2023

No unwanted outcome (%) Loss of efficacy (%) Toxicity (%) Total
Boosted ARV 35 (47.3) 5 (6.8) 34 (45.9) 74
Unboosted InSTI 18 (62.1) 11 (37.9) 0 29
NNRTI 10 (43.5) 9 (39.1) 4 (17.4) 23
Other 7 (53.8) 5 (38.5) 1 (7.7) 13
Total 70 (50.4) 30 (21.6) 39 (28) 139

ARV antiretroviral, InSTI integrase inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitors